Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?
TheFly reported on June 3 that H.C. Wainwright lowered its price target on HRTX to $2 from $4 while maintaining a Buy rating after the U.S.
Heron Therapeutics Inc. (HRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 30,046,828 | $24,040,467 | 0.25% | |
| 2. | Clearline Capital Marc Majzner | 12,235,239 | $9,789,415 | 0.51% | |
| 3. | OrbiMed Advisors Samuel Isaly | 9,816,940 | $7,854,534 | 0.16% | |
| 4. | Velan Capital Adam Morgan | 8,753,290 | $7,003,507 | 4.39% | |
| 5. | Millennium Management Israel Englander | 7,630,527 | $6,105,185 | +7% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.50 | 2,387,225 | $3,580,837.50 | 29,100,728 | 2025-08-08 | Filing | |
| $1.50 | 1,766,546 | $2,649,819.00 | 8,753,290 | 2025-08-08 | Filing | |
| $1.09 | 25,000 | $27,250.00 | 79,000 | 2023-11-17 | Filing | |
| $0.94 | 50,000 | $46,995.00 | 54,000 | 2023-11-16 | Filing | |
| $0.92 | 150,000 | $137,970.00 | 186,496 | 2023-11-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.76 | 1,504 | $7,153.63 | 10,872 | 2022-05-03 | Filing | |
| $9.73 | 300 | $2,920.35 | 3,200 | 2021-12-21 | Filing | |
| $9.73 | 250 | $2,431.93 | 2,840 | 2021-12-21 | Filing | |
| $12.31 | 300 | $3,691.95 | 3,500 | 2021-09-21 | Filing | |
| $12.30 | 250 | $3,074.10 | 3,090 | 2021-09-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,541 | $232,959 | 0.03% | |
| 2. | 28,409 | $12,125 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
10 Most Promising Cancer Stocks According to Wall Street Analysts
Regardless of the state of the economy, the pharmaceutical business has continued to be one of the healthcare market's most robust sectors thanks to the consistent need for medications, vaccinations, ...
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
TheFly reported on May 11 that HRTX saw its price target reduced to $4 from $6 while the Buy rating was reiterated in a recent research update from H.C. Wainwright analyst Brandon Folkes.
10 Best Penny Stocks Under $1 According to Hedge Funds
Penny stocks often draw renewed investor interest when risk appetite improves, and smaller companies begin participating in broader market rallies.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2026 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q4 2025 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2025 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2025 Earnings Call Transcript November 4, 2025Heron Therapeutics, Inc. misses on earnings expectations.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Heron Therapeutics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call. At this time, all participants are in a listen-only mode.
10 Hot Biotech Stocks Under $5
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Hedge Fund Resource Center